-associated MicroRNAs in Colorectal Cancer

Overview

Journal Oncol Rev

Specialty Oncology

Date 2020 Jul 21

PMID 32685110

Citations 5

Authors

Hamizah Ibrahim

Ya Chee Lim

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancerrelated death worldwide. Despite progress in treatment of cancers, CRC with mutations are resistant towards anti-EGFR treatment. MicroRNAs have been discovered in an exponential manner within the last few years and have been known to exert either an onco-miRNA or tumor suppressive effect. Here, the various roles of microRNAs involved in the initiation and progression of -regulated CRC are summarized. A thorough understanding of the roles and functions of the plethora of microRNAs associated with in CRC will grant insights into the provision of other potential therapeutic targets as well as treatment. MicroRNAs may also serve as potential molecular classifier or early detection biomarkers for future treatment and diagnosis of CRC.

Citing Articles

Advancements in gene therapies targeting mutant KRAS in cancers.

Wang Y, Bui T, Yang X, Hutvagner G, Deng W Cancer Metastasis Rev. 2025; 44(1):24.

PMID: 39820726 PMC: 11748474. DOI: 10.1007/s10555-025-10243-9.

Significant association of miRNA 34a with BRCA1 expression in pancreatic ductal adenocarcinoma: an insight on miRNA regulatory pathways in the Pakistani population.

Ali S, Adnan Y, Ahmad Z, Chawla T, Farooqui H, Adnan Ali S BMC Cancer. 2024; 24(1):1543.

PMID: 39696052 PMC: 11657824. DOI: 10.1186/s12885-024-13259-6.

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review.

Michas A, Michas V, Anagnostou E, Galanopoulos M, Tolia M, Tsoukalas N Glob Med Genet. 2023; 10(4):315-323.

PMID: 38025193 PMC: 10665125. DOI: 10.1055/s-0043-1777094.

Association of the rs8720 and rs12587 Gene Variants with Colorectal Cancer in a Mexican Population and Their Analysis In Silico.

Gallegos-Arreola M, Garibaldi-Rios A, Cruz-Sanchez J, Figuera L, Ronquillo-Carreon C, Rosales-Reynoso M Cells. 2023; 12(15).

PMID: 37566020 PMC: 10417115. DOI: 10.3390/cells12151941.

Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival.

Villanueva J, Kwong L, Han T, Martinez S, Shanahan M, Kanke M BMC Genomics. 2022; 23(1):792.

PMID: 36457077 PMC: 9716731. DOI: 10.1186/s12864-022-09018-1.

References

Ramon L, David C, Fontaine K, Lallet E, Marcaillou C, Martin-Lanneree S . Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens. Biomark Insights. 2018; 13:1177271918763357. PMC: 5858679. DOI: 10.1177/1177271918763357. View

Saud S, Li W, Morris N, Matter M, Colburn N, Kim Y . Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression. Carcinogenesis. 2014; 35(12):2778-86. PMC: 4247523. DOI: 10.1093/carcin/bgu209. View

Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y . Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28(10):1385-92. DOI: 10.1038/onc.2008.474. View

Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F . Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2014; 20(12):3338-47. DOI: 10.1158/1078-0432.CCR-13-2750. View

Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J . MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2012; 62(9):1315-26. PMC: 3787864. DOI: 10.1136/gutjnl-2011-301846. View

Hong L, Lai M, Chen M, Xie C, Liao R, Kang Y . The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res. 2010; 70(21):8547-57. PMC: 2970743. DOI: 10.1158/0008-5472.CAN-10-1938. View

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

Choo K, Soon Y, Nguyen P, Hiew M, Huang C . MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci. 2014; 21:95. PMC: 4195866. DOI: 10.1186/s12929-014-0095-x. View

Xie F, Li C, Zhang X, Peng W, Wen T . MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. Biomed Pharmacother. 2019; 119:109424. DOI: 10.1016/j.biopha.2019.109424. View

10.

Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M . MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget. 2015; 6(36):38695-704. PMC: 4770730. DOI: 10.18632/oncotarget.5735. View

11.

Tokarz P, Blasiak J . The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012; 59(4):467-74. View

12.

Li Z, Pan X, Han B, Guo X, Zhang Z, Jia J . A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013; 34(5):3159-63. DOI: 10.1007/s13277-013-0885-x. View

13.

Zenonos K, Kyprianou K . RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol. 2013; 5(5):97-101. PMC: 3682174. DOI: 10.4251/wjgo.v5.i5.97. View

14.

Roh M, Lee H, Jung S, Kim K, Lee E, Park M . Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer. Pathol Res Pract. 2018; 214(3):350-355. DOI: 10.1016/j.prp.2018.01.005. View

15.

Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T . Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res. 2011; 31(7):2453-9. View

16.

Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N . High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist. 2012; 17(6):823-9. PMC: 3380881. DOI: 10.1634/theoncologist.2012-0081. View

17.

Huang X, Lv W, Zhang J, Lu D . miR‑96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer. Int J Mol Med. 2014; 34(6):1599-605. DOI: 10.3892/ijmm.2014.1940. View

18.

Fan Q, Hu X, Zhang H, Wang S, Zhang H, You C . MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS. Cell Physiol Biochem. 2017; 44(4):1311-1324. DOI: 10.1159/000485491. View

19.

Wu Z, Liu K, Wang Y, Xu Z, Meng J, Gu S . Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer. Cancer Cell Int. 2015; 15:107. PMC: 4650312. DOI: 10.1186/s12935-015-0235-8. View

20.

Gibbons D, Lin W, Creighton C, Rizvi Z, Gregory P, Goodall G . Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009; 23(18):2140-51. PMC: 2751985. DOI: 10.1101/gad.1820209. View